The effect of protamine dosing variation on bleeding and transfusion after heparinisation for cardiopulmonary bypass

Abstract

Introduction:

Accurate dosing of protamine reversal following on-pump cardiac surgical procedures is challenging, with both excessive and inadequate administration recognised to increase bleeding risk. We aimed to examine the relationship between three ratios for heparin reversal and markers of haemostasis.

Methods:

A retrospective analysis of a prospectively collected database was undertaken at a single tertiary cardiac unit, reviewing all cases of on-pump coronary artery bypass grafts and single valve replacements from 01/01/2011 to 31/12/2015. The ratio between total intra-operative heparin and protamine was stratified to three groups (low: ≤0.6 mg per 100 IU of heparin, moderate: 0.6-1.0 and high: >1.0) and related to the primary outcome of red blood cell (RBC) transfusion, with secondary outcomes being the number of units transfused, the haemoglobin differential and mediastinal drain output at 4 hours.

Results:

Of the 803 patients identified, 338 received a blood transfusion, with 1035 units being used. Eighteen percent of individuals (145) received a low ratio, 50% (404) received a moderate ratio and 32% (254) a high ratio. Using the moderate group as a reference, the low dose group was 56.5% less likely to have received a RBC transfusion (OR 0.435; 95% CI 0.270:0.703 p=0.001) while the high dose group carried a 241% increased association with transfusion (OR 3.412; 95% CI 2.399:4.853 p<0.001). For those transfused, a lower protamine:heparin ratio was associated with a lower number of units transfused, lesser haemoglobin differential and less mediastinal drain output.

Conclusion:

Higher doses of intra-operative protamine relative to heparin are associated with greater risk of transfusion and post-operative bleeding.

Keywords

heparin protamine reversal ratio bleeding transfusion haemostasis

Get full access to this article

View all access options for this article.

References

Rosin

Holt

Heparin dose and postoperative bleeding in patients undergoing cardiopulmonary bypass. J Extra Corpor Technol 2013; 45: 228–234.

Holland

Singh

McMaster

et al . Adverse reactions to protamine sulfate following cardiac surgery. Clin Cardiol 1984; 7: 157–162.

Mochizuki

Olson

Szlam

et al . Protamine reversal of heparin affects platelet aggregation and activated clotting time after cardiopulmonary bypass. Anesth Analg 1998; 87: 781–785.

Khan

Wayne

Barker

et al . The effects of protamine overdose on coagulation parameters as measured by the thrombelastograph. Eur J Anaesthesiol 2010; 27: 624–627.

Koster

Borgermann

Gummert

et al . Protamine overdose and its impact on coagulation, bleeding, and transfusions after cardiopulmonary bypass: results of a randomized double-blind controlled pilot study. Clin Appl Thromb Hemost 2014; 20: 290–295.

Arén

Review article : Heparin and protamine during cardiac surgery. Perfusion 1989; 4: 171–181.

Gerbode

FHR

Osborn

PErkins

. The neutralization of heparin by protamine in extracorporeal circulation. J Thorac Surg 1956; 32: 612–619.

Bull

Huse

Brauer

et al . Heparin therapy during extracorporeal circulation. II. The use of a dose-response curve to individualize heparin and protamine dosage. J Thorac Cardiovasc Surg 1975; 69: 685–689.

Meesters

Veerhoek

de Lange

et al . Effect of high or low protamine dosing on postoperative bleeding following heparin anticoagulation in cardiac surgery. A randomised clinical trial. Thromb Haemost 2016; 116: 251–261.

10.

Kjellberg

Sartipy

van der Linden

et al . An adjusted calculation model allows for reduced protamine doses without increasing blood loss in cardiac surgery. Thorac Cardiovasc Surg 2016; 64: 487–493.

11.

Society of Thoracic Surgeons Blood Conservation Guideline Task Force; Ferraris

Brown

Despotis

et al . 2011 Update to The Society of Thoracic Surgeons and the Society of Cardiovascular Anesthesiologists blood conservation clinical practice guidelines. Ann Thorac Surg 2011; 91: 944–982.

12.

Nashef

Roques

Michel

et al . European system for cardiac operative risk evaluation (EuroSCORE). Eur J Cardiothorac Surg 1999; 16: 9–13.

13.

Lafeuille

M-H

Vekeman

Bailey

et al . Comparison of epoetin alfa and darbepoetin alfa dosing and costs in an inpatient population with myelodysplastic syndromes. Blood 2008; 112: 1297.

14.

Thompson

May

Choong

et al . Predicting blood loss and transfusion requirement in patients undergoing surgery for musculoskeletal tumors. Transfusion 2014; 54: 1469–1477.

15.

NHMRC/ASBT. Clinical Practice Guidelines on the Use of Blood Components. Australia, 2001.

16.

Williams

Using the margins command to estimate and interpret adjusted predictions and marginal effects. Stata Journal 2012; 12: 308–331.

17.

Estes

JW.

Clinical pharmacokinetics of heparin. Clin Pharmacokinet 1980; 5: 204–220.

18.

Jia

Tian

Ren

et al . Pharmacokinetic model of unfractionated heparin during and after cardiopulmonary bypass in cardiac surgery. J Translational Med 2015; 13: 45.

19.

Carr

Silverman

. The heparin-protamine interaction. A review. J Cardiovasc Surg (Torino) 1999; 40: 659–666.

20.

Watanabe

Hori

Iwamoto

et al . Disposition of tritium-labelled heparin in rats. J Pharmacobiodyn 1982; 5: 627–637.

21.

Meesters

Veerhoek

de Jong

et al . A pharmacokinetic model for protamine dosing after cardiopulmonary bypass. J Cardiothorac Vasc Anesth 2016; 30: 1190–1195.

22.

Butterworth

Lin

Prielipp

et al . The pharmacokinetics and cardiovascular effects of a single intravenous dose of protamine in normal volunteers. Anesth Analg 2002; 94: 514–522.

23.

Galeone

Rotunno

Guida

et al . Monitoring incomplete heparin reversal and heparin rebound after cardiac surgery. J Cardiothorac Vasc Anesth 2013; 27: 853–858.

24.

Teoh

Young

Blackall

et al . Can extra protamine eliminate heparin rebound following cardiopulmonary bypass surgery? J Thorac Cardiovasc Surg 2004; 128: 211–219.

25.

Ni Ainle

Preston

Jenkins

et al . Protamine sulfate down-regulates thrombin generation by inhibiting factor V activation. Blood 2009; 114: 1658–1665.

26.

DeLaria

Tyner

Hayes

et al . Heparin-protamine mismatch. A controllable factor in bleeding after open heart surgery. Arch Surg 1994; 129: 944–950; discussion 950–951.

27.

de Jong

Boer

Calculating the protamine dose necessary to neutralize heparin in all patients under all circumstances. J Cardiothorac Vasc Anesth 2016; 30: e6-e7.

28.

Ödling Davidsson

Johagen

Appelblad

et al . Reversal of heparin after cardiac surgery: protamine titration using a statistical model. J Cardiothorac Vasc Anesth 2015; 29: 710–714.

29.

Vonk

ABA

Veerhoek

van den Brom

et al . Individualized heparin and protamine management improves rotational thromboelastometry parameters and postoperative hemostasis in valve surgery. J Cardiothorac Vasc Anesth 2014; 28: 235–241.

30.

Shore-Lesserson

Reich

DePerio

Heparin and protamine titration do not improve haemostasis in cardiac surgical patients. Can J Anaesth 1998; 45: 10–18.

31.

De Santo

Amarelli

Della Corte

et al . Blood transfusion after on-pump coronary artery bypass grafting: focus on modifiable risk factors. Eur J Cardiothorac Surg 2013; 43: 359–366.